6 news items
Actinium Pharmaceuticals (ATNM) Poised for Breakout as Analysts Project Significant Upside
CRMD
FULC
MRNS
9 May 24
for those who prefer aggressive growth opportunities in their portfolio. The nature of biotech investments implies inherent risks, such as volatility
Ocular Therapeutix™ To Present at Two Ophthalmology Meetings, May 4-9, 2024
OCUL
3 May 24
conjunctivitis. DEXTENZA is a corticosteroid intracanalicular insert placed in the punctum, a natural opening in the inner portion of the lower eyelid
Ocular Therapeutix™ to Host Investor Day in New York City on Thursday, June 13, 2024
OCUL
1 May 24
in the punctum, a natural opening in the inner portion of the lower eyelid, and into the canaliculus, and is designed to deliver dexamethasone to the ocular
Ocular Therapeutix™ Announces Positive Phase 2 PAXTRAVA™ Glaucoma Data at the American Society of Cataract and Refractive Surgery 2024 Annual Meeting
OCUL
6 Apr 24
conjunctivitis. DEXTENZA is a corticosteroid intracanalicular insert placed in the punctum, a natural opening in the inner portion of the lower eyelid
Ocular Therapeutix™ To Present Data at the 2024 ASCRS Annual Meeting (American Society of Cataract and Refractive Surgery)
OCUL
26 Mar 24
itching associated with allergic conjunctivitis. DEXTENZA is a corticosteroid intracanalicular insert placed in the punctum, a natural opening
tbmtd9ui8hvfbb1zdf759ugv7m5h2j6lnlcd
ATXI
AUUD
BNED
11 Mar 24
is expected to report fourth-quarter financial results on March 20, 2024.
Bon Natural Life Limited
- Prev
- 1
- Next